Aditxt (ADTX) Stock Price, News & Analysis

Company Overview

Aditxt, Inc. (NASDAQ: ADTX) is a biotechnology company focused on developing technologies designed to monitor and improve the human immune system. Its work centers on immune profiling, precision health and personalized medicine, with the goal of helping healthcare providers and researchers better understand individual immune responses.

The company’s primary technology platform, AditxtScore, is designed to analyze multiple immune system biomarkers simultaneously. The platform is intended for applications including disease detection, monitoring immune responses to infections and vaccines, and supporting the development of personalized treatment strategies. Aditxt has also pursued diagnostic and health-monitoring initiatives through related businesses and partnerships.

Aditxt was founded in 2017 and is headquartered in Mountain View, California. The company has identified Amro Albanna, its co-founder and chief executive officer, as part of its leadership. Its activities primarily serve the biotechnology, clinical research and healthcare markets, although the availability and development stage of specific products may vary by program and regulatory status.

Key Stats

• Today's Range: $0.0003 to $0.0005
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $1,169.21
• Volume: 43,358 shs
• Average Volume: 81.23 million shs
• Market Capitalization: $408.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Aditxt Stock Analysis - MarketRank™

Aditxt scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Aditxt has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Aditxt has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aditxt is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aditxt is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aditxt has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ADTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aditxt does not currently pay a dividend.

Dividend Growth

Aditxt does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Aditxt to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aditxt insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.01% of the stock of Aditxt is held by insiders.

Percentage Held by Institutions

15.54% of the stock of Aditxt is held by institutions.

Company Calendar

• Today: 11/13/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ADTX
• CIK: 1726711
• Web: www.aditxt.com
• Phone: 650-870-1200
• Fax: N/A
• Employees: 26
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($100,788.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.71 million
• Net Margins: -360,152.50%
• Pretax Margin: -367,584.03%
• Return on Equity: -374.60%
• Return on Assets: -105.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: $14.34 thousand
• Price / Sales: 0.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $259.70 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 816,000
• Free Float: 816,000
• Market Cap: $408.00
• Optionable: No Data
• Beta: 1.37